Press Releases :: ProMIS Neurosciences, Inc. (PMN)

Nov 20, 2023

ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s Disease

Nov 14, 2023

ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights

Sep 8, 2023

ProMIS Neurosciences Closes $20.4 Million Private Placement Financing

Sep 6, 2023

ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 21, 2023

ProMIS Neurosciences Announces $20.4 Million Private Placement Financing

Aug 14, 2023

ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights

Jul 17, 2023

ProMIS Showcases Preclinical Data at the Alzheimer’s Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimer’s Pipeline

Jul 14, 2023

ProMIS Announces Completion of Continuance

Jul 10, 2023

ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange

Jun 30, 2023

ProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions Approved